Cited 0 times in Scipus Cited Count

Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer

DC Field Value Language
dc.contributor.authorKim, CW-
dc.contributor.authorChon, HJ-
dc.contributor.authorKim, C-
dc.date.accessioned2022-12-26T00:39:07Z-
dc.date.available2022-12-26T00:39:07Z-
dc.date.issued2021-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23467-
dc.description.abstractAlthough immune checkpoint inhibitors (ICIs) have shown promising results in the treatment of treating various malignancies, progress has been severely limited in metastatic colorectal cancer (mCRC). ICIs are effective in a fraction of patients with microsatellite instability-high mCRC but have little clinical efficacy in patients with microsatellite stable (MSS) mCRC, which accounts for 95% of mCRC cases. MSS mCRCs are considered to have intrinsic resistance to ICI monotherapy through multiple mechanisms. 1) They are poorly immunogenic because of their low tumor mutation burden; 2) frequent activation of the WNT/β-catenin signaling pathway excludes intratumoral CD8+ T cell immunity; 3) the tumor microenvironment is immunosuppressive because of the pres-ence of various immunosuppressive cells, including tumor-associated macrophages and regulatory T cells; and 4) frequent liver metastasis in MSS mCRC may reduce the efficacy of ICIs. To overcome these resistance mechanisms, combination approaches using various agents, including STING ago-nists, MEK inhibitors, VEGF/R inhibitors, WNT/β-catenin inhibitors, oncolytic viruses, and chemo/radiotherapy, are actively ongoing. Preliminary evidence of the efficacy of some has been shown in early clinical trials. This review summarizes novel combination immunotherapy strategies described in recent preclinical and clinical studies to overcome the limitations of ICI monotherapy in MSS mCRC.-
dc.language.isoen-
dc.titleCombination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer-
dc.typeArticle-
dc.identifier.pmid34638390-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507875/-
dc.subject.keywordColorectal cancer-
dc.subject.keywordImmune checkpoint inhibitor-
dc.subject.keywordImmunotherapy-
dc.subject.keywordMicrosatellite stability-
dc.subject.keywordMismatch repair proficiency-
dc.subject.keywordResistance-
dc.contributor.affiliatedAuthorKim, CW-
dc.type.localJournal Papers-
dc.identifier.doi10.3390/cancers13194906-
dc.citation.titleCancers-
dc.citation.volume13-
dc.citation.number19-
dc.citation.date2021-
dc.citation.startPage4906-
dc.citation.endPage4906-
dc.identifier.bibliographicCitationCancers, 13(19). : 4906-4906, 2021-
dc.identifier.eissn2072-6694-
dc.relation.journalidJ020726694-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Files in This Item:
34638390.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse